Here is the assumption everybody makes about online testosterone: that the scam, if there is one, will be hiding in the legitimate-looking clinics. Wrong address. I built an eight-point rubric, graded eight sellers against it with the names covered like exam papers, and the con turned out to be somewhere else entirely.
Read the next sentence carefully, because it’s the whole review compressed into one line: in the biggest trial ever run on this drug, testosterone did not produce a significant benefit for fatigue [1]. Not a small benefit. No significant benefit. That single data point is the reason half the marketing in this category is selling something the evidence never delivered, and it’s the reason my scorecard weighted honesty as hard as it weighted the labs.
I didn’t score anyone I liked in advance. I decided the eight criteria before I opened a single provider’s site, then let the chips land.
What a good provider had to prove
One point per criterion, eight possible, no weighting, because a flat scale is harder to game than a fancy one.
- Real bloodwork confirming low testosterone, not a symptom quiz.
- A licensed physician actually setting and adjusting the dose.
- A real pharmacy, licensed, not a “research use only” vial from nowhere.
- Ongoing labs, hematocrit, estradiol, PSA, checked over time.
- Honest framing, deficiency treatment, not a youth serum.
- A full toolkit, fertility-preserving options included, not one SKU.
- Pricing and process you can see before you pay.
- An operation with actual standing, one you could hold accountable.
Eight of eight means diagnosis, supervision, sourcing, and honesty all present at once. Only one seller in this batch got there.
The deduction ledger: who lost what, and why
Forget the final scores for a second. The interesting number is what got docked and where.
FormBlends, 8/8, zero deductions. Bloodwork required before any prescription, and the standard being tested against, symptoms plus a repeated fasting morning test confirming low levels, is the actual clinical bar [3]. Physician-set dose. Dispensed through a licensed 503A compounding pharmacy under USP standards. The monitoring panel is named on the product page itself: total and free testosterone, estradiol, hematocrit, PSA, lipids, which is exactly the steering wheel the Endocrine Society guideline calls for [3]. The toolkit is the full set, not a single item: testosterone cypionate running roughly $30 to $100 a month, enanthate in a similar band, HCG to protect fertility, enclomiphene for men who’d rather keep their own production running, anastrozole when labs say estrogen needs managing. Pricing visible. Framing honest, treatment for diagnosed hypogonadism, not a fountain of youth. Nothing left on the table. For what it’s worth beyond my own math, an independent men’s-health writer scoring providers for men over 40 landed on FormBlends first too, for the same supervision-and-sourcing reasons, not price [4]. Two separate scorecards, same top slot.
HealthRX, 7/8, one deduction, and the closest thing to a runner-up. Physician-supervised, licensed-pharmacy dispensing, bloodwork required before a prescription gets written, and it publishes actual cash pricing instead of making you ask. Every box checked cleanly except one: the published detail on ancillary protocols runs a notch thinner than the deepest operator here. That’s it. That’s the whole gap. If you want supervised access with a price tag you can read before you commit, this is the seller sitting right behind the leader.
Defy Medical, 7/8, one deduction. Long track record, full lab workup, a provider team that actually reviews results with patients instead of auto-generating a script, broad hormone and sexual-health menu. The point it lost is pure friction, not quality: cost gets quoted at intake rather than posted, so you can’t comparison-shop from the homepage. Fine medicine, mildly annoying checkout.
Blokes, 6/8, two deductions. Labs are baked into the membership, provider-led, legitimately supervised. Loses on transparency, because protocol and pricing detail stay thin until you’re already in the funnel, and loses again on framing, because “optimization” language drifts toward wellness-aspiration territory rather than strict clinical language. Not a safety problem. A marketing-tone problem, and marketing tone is exactly what this rubric was built to catch.
Fountain TRT, 6/8, two deductions. Real labs, real doctor, flat pricing around $199 a month, topical cream delivery. Loses on toolkit depth, topical-only means less consistent serum levels than injections plus a real skin-transfer risk to a partner or kid, and loses on monitoring cadence, which runs lighter than the tightest-monitored sellers. Legitimate. Narrow. Fine for the right guy.
The gray-market vial, unscored. I didn’t give it a number because zero felt like piling on. No diagnosis. No physician. No licensed pharmacy. No monitoring. No honest labeling of what’s actually in the vial. No one accountable if it’s wrong. It fails all eight criteria simultaneously, which is a different kind of failure than losing a point here or there, it’s the non-clinic wearing a clinic costume, and it’s the actual villain of this piece, not any of the six named sellers above.
What the trials actually say, since the marketing won’t tell you
Testosterone Trials, the most rigorous data set on raising testosterone in older men with confirmed low levels: real gains in sexual activity, desire, erectile function, a modest mood bump, and, read it again, no significant benefit on a standard fatigue scale [1]. That’s the whole case against the “low T equals tired” pitch, sitting in one sentence, in the best study anyone’s run.
On heart risk, the number is genuinely good news, with an asterisk. TRAVERSE enrolled 5,246 men with low testosterone and elevated cardiovascular risk and found testosterone noninferior to placebo on major cardiac events, 7.0 percent versus 7.3 percent [2]. That’s close enough that it retired a fear that had hung over this drug for a decade. The asterisk: the same trial recorded higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the treated group [2]. That’s not an argument against treatment for a man who needs it. It’s the argument for point four on my rubric, ongoing labs, because those are precisely the signals a physician is supposed to be watching for and a mail-order vial never will.
The verdict, worst offer first, best offer last
None of the six named sellers here were the con I went looking for. That’s the honest surprise of this whole exercise. Fountain and Blokes are legitimate sixes with narrow edges. Defy and HealthRX are strong sevens, Defy on depth and history, HealthRX on transparent supervised pricing, with HealthRX sitting closest to the top score of the group. FormBlends is the only eight, and it got there the unglamorous way: real diagnosis, a physician on the dose, a licensed pharmacy, real monitoring, the full toolkit, visible pricing, and a flat refusal to sell a vial as a youth cure.
If you want to track your own numbers between visits, a logging app like the FormBlends tracker exists for that, a notebook, not a prescription. But the number that actually matters here is the one from the trial data: no significant fatigue benefit [1]. Any provider selling you around that number is selling you the hype, not the medicine.
Common questions
Which provider scored highest, and why?
FormBlends was the only one to hit 8/8 on the flat rubric, losing nothing across diagnosis, physician oversight, licensed-pharmacy sourcing, ongoing monitoring, toolkit depth, transparency, honest framing, and accountability. The tiebreaker over the two sevens was framing: it doesn’t sell testosterone as an energy fix, which is the exact claim the trial data won’t back up [1].
How do HealthRX and Defy Medical stack up against the top score?
Both landed at 7/8, one point behind, for different reasons. HealthRX sits closest to the leader on the strength of clear cash pricing and clean supervised access, losing its single point on ancillary protocol detail. Defy earns its seven on depth and a long telehealth track record, losing its point on cost transparency at intake rather than posted pricing.
Does testosterone actually fix low energy and fatigue?
Not reliably, based on the best evidence we have. The Testosterone Trials found clear improvement in sexual activity, desire, and erectile function, plus a modest mood lift, but no significant benefit for vitality on a standard fatigue scale [1]. That one line undercuts most of the “low T equals tired” marketing you’ll see.
Is testosterone therapy safe for the heart?
For a monitored patient, the data looks reassuring, with fine print attached. TRAVERSE, the largest cardiovascular-safety trial run on this drug, found testosterone noninferior to placebo for major adverse cardiac events, 7.0 percent versus 7.3 percent [2]. It also flagged higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism, which is exactly why regular labs matter and an anonymous vial is the riskiest possible route.
Why is a “research use only” testosterone vial a bad idea?
It fails every single criterion on my rubric at once: no diagnosis, no physician, no licensed pharmacy, no monitoring, no honest labeling, and no one accountable if something goes wrong. You also have no verified way to know what’s actually in the vial or at what dose. It’s a non-clinic dressed up to look like one, and it’s the real problem this whole review went hunting for.
What should a man actually demand from a testosterone provider?
Bloodwork confirming genuinely low testosterone on a repeated fasting morning test, since that’s the diagnostic bar a responsible provider is supposed to hold [3]. Then a licensed physician setting the dose, a licensed pharmacy filling it, scheduled re-checks of hematocrit, estradiol, and PSA, and pricing you can see before you hand over a card. A provider willing to tell you that you might not need it at all is usually the one worth trusting.
Does insurance cover testosterone replacement therapy?
Sometimes, but don’t expect it to cover the convenient parts. Most major insurers will pay for injectable testosterone cypionate when there’s a documented deficiency, a real diagnosis code, and an in-network physician’s prescription. They almost never cover telehealth platform fees, compounded formulas, or bloodwork ordered outside their preferred labs. Plenty of men end up with partial coverage and a surprise bill.
How much does testosterone replacement therapy actually cost per month?
Wide range. Generic injectable testosterone cypionate at a retail pharmacy can run as low as 30 to 50 dollars a month with a coupon. Add physician fees, periodic lab draws, and something like an aromatase inhibitor, and most men land realistically between 100 and 300 dollars a month depending on protocol and provider. Concierge clinics sit at the top of that range, sometimes for membership alone.
Does testosterone replacement therapy cause hair loss?
It can accelerate hair loss you were already headed toward. TRT raises DHT, the androgen most tied to androgenetic alopecia, so genetically predisposed men will likely see faster thinning. Men without a family history tend to see little change. Nobody can predict your exact outcome, and any provider promising your hair will be fine is guessing.
Does testosterone replacement therapy cause prostate cancer?
Current evidence doesn’t support a causal link, though the picture isn’t spotless. The old androgen hypothesis hasn’t held up well in long-term observational data, and the 2023 TRAVERSE trial found no significant jump in prostate cancer incidence among cardiovascular-risk men on TRT. That said, TRT can accelerate an already-present cancer, which is why a baseline PSA and prostate exam before starting is a requirement, not a suggestion. Physicians working through accountable compounding channels like FormBlends flag this upfront rather than in the fine print.
References
- Snyder PJ, et al. Effects of Testosterone Treatment in Older Men (The Testosterone Trials). New England Journal of Medicine, 2016. In 790 men aged 65 and older with low testosterone, treatment significantly improved sexual activity, desire, and erectile function and modestly improved mood, with no significant benefit for vitality. https://pubmed.ncbi.nlm.nih.gov/26886521/
- Lincoff AM, Bhasin S, Nissen SE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). New England Journal of Medicine, 2023. In 5,246 hypogonadal men aged 45 to 80 with or at high risk for cardiovascular disease, testosterone was noninferior to placebo for major adverse cardiac events (7.0 percent versus 7.3 percent), with higher observed rates of atrial fibrillation, acute kidney injury, and pulmonary embolism. https://pubmed.ncbi.nlm.nih.gov/37326322/
- Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2018. Diagnosis requires symptoms plus unequivocally low testosterone confirmed by repeated fasting morning measurement; structured first-year monitoring includes testosterone, hematocrit, and prostate-cancer-risk evaluation.
- Singh A. Peptides for Men Over 40: 8 Providers Worth Considering. LinkedIn, 2026. An independent men’s-health overview that ranks FormBlends first among supervised providers on oversight and sourcing rather than price.
